摘要
目的比较人肝细胞核因子-1β(hepatocyte nuclear factor-1β,HNF1β)在不同病理类型肝癌中的表达差异。方法选取术后病理确诊的原发性肝细胞癌(hepatocellular carcinoma,HCC)和肝内胆管细胞癌(intrahepatic cholangiocarcinoma,ICC)患者各52例。记录并比较两组患者基本情况及预后情况,采用免疫组织化学技术检测两组肿瘤组织HNF1β表达情况。结果 47例HCC组患者术后出现复发,其中7例病理类型改变为ICC;HCC组患者HNF1β阳性表达率为44.2%,ICC组患者HNF1β阳性表达率为86.5%,两者比较,差异具有统计学意义(P<0.05)。HCC组中病理类型改变组HNF1β阳性表达率为100%,病理类型未改变组HNF1β阳性表达率为35.6%,两者比较,差异具有统计学意义(P<0.05)。HNF1β在HCC中的高表达与组织学分级更差、K7表达和K19表达存在相关性(r=0.406,P=0.033;r=0.462,P=0.016;r=0.397,P=0.048)。结论 HNF1β在HCC中表达低于ICC,且与组织学分级、K7表达和K19表达相关。
Objective To compare the expression of hepatocyte nuclear factor-1β( HNF1β) in liver cancer of different pathological types. Methods Fifty-two patients each with postoperative pathologically diagnosed primary hepatocellular carcinoma( HCC) and intrahepatic cholangiocarcinoma( ICC) were selected. The basic condition and prognosis of the two groups of patients were recorded and analyzed. Immunohistochemistry tests were used to examine the expression of HNF1β in the two groups of tumor tissues. Results Forty-seven cases of HCC patients showed recurrence after operation,among which 7 cases had their pathological types changed to ICC. The positive expression rate of HNF1β was 44. 2% in the HCC group,and was 86. 5% in the ICC group,which difference was statistically significant( P〈0. 05). Besides,in the HCC patients whose pathological type changed to ICC,the positive expression rate of HNF1β turned to 100%,which was35. 6% in the HCC patients with unchanged pathological types,and the difference was statistically significant( P〈0. 05).Finally,high expression of HNF1β in HCC was correlated with worse histological grade,K7 expression and K19 expression( r = 0. 406,P = 0. 033; r = 0. 462,P = 0. 016; r = 0. 397,P = 0. 048). Conclusion HNF1β showed lower expression in HCC than in ICC,and is correlated with histological grade,K7 expression and K19 expression.
作者
吴伟
王亚奇
尚闯
蔡建平
Wu Wei;Wang Yaqi;Shang Chuang;Cai Jianping(Department Two of General Surgery, Zhumadian Central Hospital,Zhumadian 463000, China;Department of Hepatobiliary, Pancreatic and Splenic Surgery,Zhumadian Central Hospital, Zhumadian 463000, China;Department of Gastrointestinal Surgery, Henan Cancer Hospital, Zhengzhou 450008, China;Department of Hepatobiliary and Pancreatic Surgery, Henan Provincial People's Hospital, Zhengzhou 450003 ,China)
出处
《实用肿瘤杂志》
CAS
2018年第3期246-249,共4页
Journal of Practical Oncology
关键词
癌
肝细胞/病理学
胆管肿瘤/病理学
肝/细胞学
胆管
肝内/病理学
基因表达
免疫组织化学
carcinoma
hepatocellular/pathology
bile duct neoplasms/pathology
liver/cytology
bile ducts
intrahepatic/pathology
gene expression
immunohistochemistry